NeoGenomics Inc (NEO) — Capital Reinvestment Ratio

Latest as of June 2026: 0.41x

NeoGenomics Inc (NEO) has a Capital Reinvestment Ratio of 0.41x as of June 2026, meaning it reinvests 0% of its operating cash flow ($19.96 Million) in capital expenditures ($8.22 Million). Check NEO intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.41x
Capex / Operating Cash Flow

Operating Cash Flow

$19.96 Million
USD

Capital Expenditures

$8.22 Million
USD

Data as of

Jun 2026
Most recent filing

NeoGenomics Inc Capital Reinvestment Ratio (2011–2025)

This chart tracks NeoGenomics Inc's Capital Reinvestment Ratio across 11 annual periods. For the full cash flow conversion analysis, see NeoGenomics Inc (NEO) cash conversion ratio.

Annual Capital Reinvestment Ratio for NeoGenomics Inc (2011–2025)

Year-by-year Capital Reinvestment Ratio for NeoGenomics Inc from 2011 to 2025. See NeoGenomics Inc (NEO) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2025 5.16x $5.23 Million $27.01 Million ▼ -11.7%
2024 5.85x $7.02 Million $41.06 Million ▼ -70.7%
2020 19.93x $1.46 Million $29.10 Million ▲ +2225.2%
2019 0.86x $23.37 Million $20.03 Million ▲ +168.2%
2018 0.32x $44.79 Million $14.31 Million ▼ -57.9%
2017 0.76x $18.04 Million $13.69 Million ▲ +116.3%
2016 0.35x $21.48 Million $7.54 Million ▲ +1.3%
2015 0.35x $6.39 Million $2.21 Million ▼ -13.2%
2014 0.40x $9.45 Million $3.77 Million ▼ -55.8%
2013 0.90x $2.23 Million $2.01 Million ▼ -93.1%
2011 13.00x $69.00K $897.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow